Advertisement
UK markets close in 30 minutes

  • FTSE 100

    7,817.48
    -148.05 (-1.86%)
     

  • FTSE 250

    19,363.22
    -335.67 (-1.70%)
     

  • AIM

    739.83
    -10.45 (-1.39%)
     

  • GBP/EUR

    1.1703
    -0.0008 (-0.07%)
     

  • GBP/USD

    1.2444
    -0.0003 (-0.02%)
     

  • Bitcoin GBP

    49,984.89
    -1,655.22 (-3.21%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • S&P 500

    5,046.89
    -14.93 (-0.29%)
     

  • DOW

    37,783.59
    +48.48 (+0.13%)
     

  • CRUDE OIL

    85.61
    +0.20 (+0.23%)
     

  • GOLD FUTURES

    2,391.50
    +8.50 (+0.36%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • HANG SENG

    16,248.97
    -351.49 (-2.12%)
     

  • DAX

    17,745.99
    -280.59 (-1.56%)
     

  • CAC 40

    7,921.70
    -123.41 (-1.53%)
     
Money:

How to avoid tax creep in retirement

The state pension went up 8.5% in April, but frozen thresholds mean pensioners will be paying more tax

UK's Indivior to seek injunction after rival gets FDA approval for generics

Reuters - UK Focus

June 15 (Reuters) - Britain's Indivior (Frankfurt: 2IVA.F - news) said on Friday it would pursue all legal remedies, including seeking an immediate injunction against the U.S Food and Drug Administration's (FDA) decision to approve the first generic versions of Suboxone Film, an opioid addiction treatment.

Indivior, which was spun out from Reckitt Benckiser (Xetra: A0M1W6 - news) in 2014, stuck to its 2018 guidance saying that until the details of Dr. Reddy's market entry of the drug's generic version is confirmed.

The company, however, warned that Dr.Reddy's launch could "potentially result in a rapid and material loss of market share for Suboxone Film in the U.S., an effect that could occur within months of a successful launch of a generic film alternative into the U.S. market." (Reporting By Justin George Varghese in Bengaluru; editing by David Evans)